The bio-CDMO blues
Japanese chemical companies are now entering the contract manufacturing operation (CDMO) of biopharmaceuticals. However, they are running into barriers in their country, such as the lack of process development funding in the AMED budget.
https://miyata-bio.net/column/0000380/
この記事が気に入ったらサポートをしてみませんか？